# EDGAR Filing Document

**Accession Number:** 0001907108
**File Stem:** 0001193125-26-193935
**Filing Date:** 2026-4
**Character Count:** 4198
**Document Hash:** c10af4c7c447b51bd84662db4ff6f580
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-193935.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001193125-26-193935

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexeo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001907108
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854012572
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41855
- **FILM NUMBER:** 26920002

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 547-9879

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE<br>SECURITIES EXCHANGE ACT OF 1934**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2

**LEXEO THERAPEUTICS, INC.**

**(Name of Registrant as Specified In Its Charter)**

------

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

------

![img243671806_0.jpg](img243671806_0.jpg)

------

![img243671806_1.jpg](img243671806_1.jpg)Your **Vote** Counts!**LEXEO THERAPEUTICS, INC.**2026 Annual MeetingVote by June 24, 202611:59 PM ETLEXEO THERAPEUTICS, INC.345 PARK AVENUE SOUTH, FLOOR 6NEW YORK, NY 10010V96051-TBDYou invested in LEXEO THERAPEUTICS, INC. and it's time to vote!You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 25, 2026.**Get informed before you voteView the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by submitting your request prior to June 11, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.For complete information and to vote, visit **www.ProxyVote.com** Control #**Smartphone users**Point your camera here and vote without entering a control number**Vote Virtually at the Meeting\*** June 25, 202610:00 AM ETVirtually at:www.virtualshareholdermeeting.com/LXEO2026\*Please check the meeting materials for any special requirements for meeting attendance.**Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT**This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.**Board RecommendsVoting Items**1. The election of Paula HJ Cholmondeley, Brenda Cooperstone and R. Nolan Townsend as Class III directors. **Nominees:**Paula HJ Cholmondeley**For**Brenda Cooperstone**For**R. Nolan Townsend**For**2. The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.**ForNOTE:** In their discretion, the proxyholders will vote on such other business as may properly come before the meeting or any adjournment or postponement thereof.

------